Indian PM's balancing act: Patents or access to meds?
This article was originally published in Scrip
Executive Summary
The tug-of-war between civil society groups backing Indian drug manufacturers and global pharma firms on intellectual property (IP) laws is taking center stage as Indian Prime Minister Narendra Modi prepares for a keenly followed official visit to the US starting 26 September.